Biography:
Dr. Manyasreeprapti Yendamuri is a Medical Affairs professional with expertise in medical strategy, scientific communications, evidence evaluation, and cross-functional medical initiatives. She currently serves as Therapy Lead – Medical Affairs at Hetero Labs, where she contributes to medical strategy and scientific initiatives across a diverse therapeutic portfolio, with a focus on advancing evidence-based healthcare and therapeutic innovation. Her previous industry experience includes collaborations with Eli Lilly and Sanofi.
Her academic and scientific interests span oncology, translational research, molecular biology, genomics, and biomarker-driven approaches to cancer management. Her research experience includes investigating epithelial–mesenchymal transition (EMT) markers in advanced cancers, providing a scientific foundation for her interests in tumor biology, disease progression, and emerging therapeutic strategies.
She holds a Doctor of Pharmacy degree from Manipal Academy of Higher Education, India, and a Master of Science in Clinical and Experimental Therapeutics from the University of Georgia, USA. Her professional and scientific interests focus on emerging oncology therapeutics, precision medicine, biosimilars, and bridging advances in cancer treatment with equitable access to care globally.